Skip to content
Life Sciences Series B Founded 2016

Wellmarker Bio

Developer of biomarker-based therapeutics for the treatment of cancer. The company has a drug pipeline of small molecules (WM-S1), antibodies(WM-A1), and protein (WM-P1) therapies in the preclinical stage targeting various cancers including colon, breast, NSLC, liver, and prostate. WM-S1 is CRG targeted inhibitor and WM-A1 is an antibody targeting cancer immunotherapy-related genes (CMG). The company was founded in…

📍 Seoul, South Korea · Genomics,

Funding snapshot

Last roundSeries B
Amount$16M
Date8 July 2019
Total raised$45M
Team size5

About

Developer of biomarker-based therapeutics for the treatment of cancer. The company has a drug pipeline of small molecules (WM-S1), antibodies(WM-A1), and protein (WM-P1) therapies in the preclinical stage targeting various cancers including colon, breast, NSLC, liver, and prostate. WM-S1 is CRG targeted inhibitor and WM-A1 is an antibody targeting cancer immunotherapy-related genes (CMG). The company was founded in 2016 and headquartered in Seoul, South Korea. It has raised $45.2M in series b funding, with backing from Orbit Partners, bric-investment.com, NH Investment & Securities, HB Investment, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Immunotherapy, Life Sciences - Oncology space. Its offerings span Oncology - In-Vitro Diagnostic Tests - Diversified and Genomics - Genomics Research - Biomarker Discovery.

Business model

Oncology > In-Vitro Diagnostic Tests > Diversified,

Genomics > Genomics Research > Biomarker Discovery

Institutional investors

Orbit Partners bric-investment.com NH Investment & Securities HB Investment Cytogen Mirae Asset Venture Korean Development Bank Gaia Ventures KB Securities Magellan Technology Investment Weed Win Investment IBK Capital The Wells Investment Meritz Securities Yozma Group Korea

Latest coverage

No articles yet.

Raising like Wellmarker Bio?

Analyze your pitch deck before your next raise.

Analyze My Deck →